Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 1015-1021

  Mizokami, Fumihiro ^a   Shibasaki, Masataka ^a   Yoshizue, Yasunori ^a   Noro, Takeshi ^a   Mizuno, Tomohiro ^b   Furuta, Katsunori ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

Elderly patients; Methicillin resistant Staphylococcus aureus; Pharmacodynamics; Pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ERUPTION; DRUG HALF LIFE; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEPHROTOXICITY; NURSING HOME; OBSERVATIONAL STUDY; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SEPSIS; STAPHYLOCOCCAL PNEUMONIA; SURVIVOR; CROSS INFECTION; JAPAN; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; FEMALE; HUMANS; JAPAN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84881294548     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S50238     Document Type: Article

References (27)

1. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued Aug 2003. Am J Infect Control. 2003;31:481-498.
2. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
3. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867-903.
4. Diekema DJ, Pfaller MA, Schmitz FJ, et al; SENTRY Participants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;15:S114-S132.
5. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854-3862.
6. Osmon S, Ward S, Fraser VJ, Kollef MH. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest. 2004;125:607-616.
7. Chung DR, Song JH, Kim SH, et al; Asian Network for Surveillance of Resistant Pathogens Study Group. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184:1409-1417.
8. Ucgun I, Dagli CE, Kiremitci A, Yildirim H, Ak G, Aslan S. Effects of isolation rooms on the prevalence of hospital acquired pneumonia in a respiratory ICU. Eur Rev Med Pharmacol Sci. 2013;1:2-8.
9. Tacconelli E, De Angelis G. Pneumonia due to methicillin-resistant Staphylococcus aureus: clinical features, diagnosis and management. Curr Opin Pulm Med. 2009;15:218-222.
10. Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31:21-24.
11. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42 Suppl 1:S35-S39.
12. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925-942.
13. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006;130:947-955.
14. Feely J, Coakley D. Altered pharmacodynamics in the elderly. Clin Geriatr Med. 1990;6:269-283.
15. Liu GG, Christensen DB. The continuing challenge of inappropriate prescribing in the elderly: an update of the evidence. J Am Pharm Assoc. 2002;42:847-857.
16. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45:945-948.
17. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17:571-584.
18. Seki M, Watanabe A, Mikasa K, Kadota J, Kohno S. Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society guidelines. Respirology. 2008;13: 880-885.
19. Clinical and Laboratory Standards Institute. 2008. M100-S18. Performance standards for antimicrobial susceptibility testing, 18th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Ki{dotless}zi{dotless}larslanoǧlu MC, Sancak B, Yaǧci{dotless} S, Hasçelik G, Unal S. Evaluation of methicillin-resistant Staphylococcus aureus bacteremia and comparison of prognosis according to vancomycin MIC values: experience of the last ten years. Mikrobiyol Bul. 2013;47:199-210. Turkish.
21. Castillo JS, Leal AL, Cortes JA, et al. Mortality among critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia: a multicenter cohort study in Colombia. Rev Panam Salud Publica. 2012;32:343-350.
22. Chen LY, Chen LK, Chang CW, et al. Treatment of community-onset methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: a hospital-based study. Arch Gerontol Geriatr. 2012;55:152-156.
23. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398-2402.
24. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166: 2138-2144.
25. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315-3320.
26. Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect. 2008;14: 116-123.
27. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:1536-1542.